2024-513986-38-00招募中2 期
PAXIPEM : Multicenter phase II study of axitinib +/- pembrolizumab in first line treatment for patients with locally advanced or metastatic papillary renal cell carcinoma (PRCC)
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 72
- 试验地点
- 13
- 主要终点
- Objective response rate (ORR)
研究概览
简要总结
To evaluate the efficacy of axitinib + pembrolizumab versus axitinib in patients with locally advanced or metastatic type 2 papillary renal carcinoma in first-line treatment.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years on the day of signing informed consent.
- •Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
- •I11.Patients of childbearing potential accepting to use effective contraception or abstain from heterosexual activity during study treatment through 4 months after the last dose of pembrolizumab treatment (or 7 days after the last dose of axitinib as monotherapy) or be surgically sterile.
- •Signed and dated approved informed consent form before any study specific procedures or assessments.
- •Metastatic or locally advanced (inoperable) type 2 or mixed PRCC, histologically confirmed by central review: FFPE blocks (or all HES and IHC slides) with the initial histology report must be sent for central reading before confirmation of inclusion in the study.
- •No prior systemic treatment for renal cancer (chemotherapy, immunotherapy, antiangiogenic drugs, or treatment under evaluation) even in adjuvant setting.
- •At least one measurable site of disease according to RECIST v1.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 1 evaluated within 7 days prior to the date of inclusion.
- •In case of prior radiation therapy, discontinuation of irradiation for at least 3 weeks before first dose of study treatment, with at least 1 site kept/preserved for evaluation. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤ 2 weeks - limited field (<10% of the whole body)) to non-CNS disease.
- •Adequate bone-marrow, hepatic, and renal functions within 7 to 9 days prior to randomization, with: - Hemoglobin ≥ 9.0 g/dl ou 5.6 mmol/l, neutrophils ≥ 1 500/mm3 (1.5 G/l), Platelets ≥ 100 000/mm3 (100 G/l), - Serum creatinine ≤ 2 x ULN OR creatinine clearance ≥ 50 ml/min/1.73m2 (calculated using either MDRD or CKD-EPI formula), - AST and ALT ≤ 2.5 x ULN (or ≤ 5 x ULN in case of liver metastasis), - Total serum bilirubin ≤ 1.5 x ULN (or direct bilirubin ≤ ULN for participants with total bilirubin levels >1.5 × ULN),
- •Absence of significant proteinuria (<2+) confirmed by urinary dipstick test. If the dipstick test is ≥ 2+, proteinuria will be quantitated on a complete 24h urine sample (< 1 g/l of protein/24h sample).
- •Covered by a medical/health insurance.
排除标准
- •Presence of brain metastases on Magnetic Resonance Imaging (MRI) or Computed Tomography-scan (CT-scan) performed within 28 days prior to randomization. Patients with a history of brain metastases treated by surgery or stereotactic surgery, with normal brain MRI or CT-scan are allowed to participate.
- •Any active acute or chronic or uncontrolled infection/disorder that would impair the ability to evaluate the patient or the ability for the patient to complete the study.
- •Known history of active TB (Bacillus Tuberculosis).
- •Interstitial lung disease, respiratory insuffisancy whatever the cause.
- •Prior (non-infectious) pneumonitis requiring systemic corticosteroid therapy or current pneumonitis.
- •Inability to swallow oral medications, or presence of active inflammatory bowel disease, partial or complete bowel obstruction or chronic diarrhea.
- •History of severe hypersensitivity to another monoclonal antibody.
- •Known hypersensitivity to the active substances or to any of the excipients.
- •Receiving or having received immunosuppressive therapy or corticosteroids within 1 month prior to inclusion (except for hydrocortisone for substitution purposes).
- •Live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette–Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed. COVID-19 vaccine is allowed if non-living/inactivated.
- •Psychological, familial, sociological, or geographical conditions that would limit compliance with study protocol requirements or known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
- •Metastases with high risk of nervous compression or bone lesion with high risk of fracture.
- •Inclusion in another clinical trial, except for supportive care trials.
- •Pregnant or breastfeeding woman or patient expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 4 months after the last dose of study treatment (mandatory negative serum or urinary pregnancy test at study entry for all women of childbearing potential).
- •Under or requiring tutorship or curatorship.
- •Prior history of other malignancies other than PRCC (except for curatively treated basal cell or squamous cell carcinoma of the skin or in situ uterine cervix carcinoma) unless the subjects has been free of the disease for at least 5 years.
- •Major surgical procedure, open biopsy, or serious none healing wound within 28 days prior to inclusion.
- •Significant cardiovascular disease, including: -Disorder of left ventricular function with a left ventricular ejection fraction (LVEF) < 50%, -Uncontrolled arterial hypertension under adapted medication: systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 90 mmHg or both despite appropriate therapy, blood pressure must be monitored and controlled before inclusion, or patients under 3 antihypertensive therapies at screening, -Myocardial infarction, severe angina, or unstable angina within 6 months prior to inclusion, -History of serious ventricular arrhythmia (ie ventricular tachycardia or ventricular fibrillation), -Cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with anti-arrhythmic medication), -Coronary or peripheral artery bypass graft or active coronary stent within 6 months prior to inclusion, -Veinous thrombosis or pulmonary embolism within 6 months prior to inclusion.
- •Any anti-coagulation therapy except prophylactic low dose.
- •Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed.
- •History of any allograft.
- •Known history of HIV or HBV infection, or known active HCV infection.
结局指标
主要结局
Objective response rate (ORR)
Objective response rate (ORR)
次要结局
- The duration of response (DOR)
- The best overall response (BOR),
- The progression-free survival (PFS),
- The overall survival (OS),
- The safety according to NCI CTC-AE v5.
研究者
Coordinating investigators
Scientific
Centre Leon Berard
研究点 (13)
Loading locations...
相似试验
招募中
3 期
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Rheumatoid Arthritis who are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate (SELECT-COMPARE)Rheumatoid arthritis2022-501017-31-00Abbvie Deutschland GmbH & Co. KG489
招募中
3 期
Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCCNCT07267806Linhui Peng326
招募中
2 期
A Study of Atezolizumab in Patients with Locally Advanced, Unresectable Stage III Non−Small Cell Lung Cancer who have already received chemotherapy and radiotherapy2023-503756-27-00F. Hoffmann-La Roche AG13
招募中
3 期
A Clinical Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer2023-506576-27-00Janssen - Cilag International170
招募中
2 期
Multicenter, open-label, phase II study in patients with immunoglobulin M monoclonal gammopathy of unknown significance and Myelin Associated Glycoprotein antibodies related polyneuropathy and Zanubrutinib Treatment2023-505933-29-00University Medical Center Utrecht42